I like huge plays, as in H U G E . :-)
If, it's a big IF because DROP is still a stinky pinkie stock, the Macular clinical trial is good and a pharma deal is signed, the barrier to entry is extremely high for competitors.
It's a long shot at this point but if the big pharma angle hits, a lot of us are going to retire early.
But don't hold your breath though because DROP is still a stinky pinkie stock.
$DROP